Wright D G, LaRussa V F, Salvado A J, Knight R D
Department of Hematology, Walter Reed Army Institute of Research, Washington, DC 20307-5100.
J Clin Invest. 1989 Apr;83(4):1414-8. doi: 10.1172/JCI114031.
Granulocyte-macrophage progenitors (CFU-GM) from four patients with childhood onset cyclic neutropenia demonstrated abnormal in vitro proliferative responses to purified, recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) when examined in detailed dose-response studies. Marrow aspirate specimens were obtained for these studies from cyclic neutropenia patients (both during neutropenic nadirs and during recovery phases of cycles), from leukemia patients in remission who had received myelosuppressive chemotherapy, and from healthy normal volunteers. Nucleated marrow cells were then isolated by density-gradient centrifugation and cryopreserved to permit studies of CFU-GM from patients and controls to be carried out at the same time and in replicate. Maximum clonal growth of CFU-GM from normal subjects and from individuals recovering from drug-induced myelosuppression was elicited by 20-100 pmol/liter rhGM-CSF, and the CSF concentrations that induced half-maximal responses (ED50) were between 1.0 and 3.0 pmol/liter. In contrast, maximum growth of CFU-GM from the cyclic neutropenia patients required greater than or equal to 1.0 nmol/liter rhGM-CSF and ED50's were greater than 30.0 pmol/liter. These abnormalities in the GM-CSF responsive growth of myeloid progenitors were independent of cycle time and were most apparent with the predominantly neutrophilic 7-d CFU-GM. Moreover, differences in the growth of 14-d CFU-GM could be attributed mostly if not entirely to differences in the generation of neutrophilic colonies. These findings indicate that childhood onset cyclic neutropenia is associated with an underlying disturbance in the GM-CSF responsive growth of myeloid progenitors committed to neutrophilic differentiation.
在详细的剂量反应研究中,对4例儿童期起病的周期性中性粒细胞减少症患者的粒细胞-巨噬细胞祖细胞(CFU-GM)进行检测时,发现其对纯化的重组人粒细胞-巨噬细胞集落刺激因子(rhGM-CSF)的体外增殖反应异常。从周期性中性粒细胞减少症患者(中性粒细胞减少最低点和周期恢复期)、接受过骨髓抑制化疗且处于缓解期的白血病患者以及健康正常志愿者获取骨髓穿刺标本用于这些研究。然后通过密度梯度离心分离有核骨髓细胞并进行冷冻保存,以便同时对患者和对照的CFU-GM进行重复研究。正常受试者和从药物诱导的骨髓抑制中恢复的个体的CFU-GM最大克隆生长由20 - 100 pmol/升的rhGM-CSF引发,诱导半数最大反应(ED50)的CSF浓度在1.0至3.0 pmol/升之间。相比之下,周期性中性粒细胞减少症患者的CFU-GM最大生长需要大于或等于1.0 nmol/升的rhGM-CSF,且ED50大于30.0 pmol/升。髓系祖细胞GM-CSF反应性生长的这些异常与周期时间无关,在主要为嗜中性粒细胞的7天CFU-GM中最为明显。此外,14天CFU-GM生长的差异如果不是完全归因于嗜中性粒细胞集落生成的差异,也大多可以归因于此。这些发现表明,儿童期起病的周期性中性粒细胞减少症与致力于嗜中性粒细胞分化的髓系祖细胞GM-CSF反应性生长的潜在紊乱有关。